Skip to content

Study · Non-randomized trial · 2023

2 results

Reduced eye gaze during facial emotion recognition in chronic depression: Effects of intranasal oxytocin.

Vehlen A, Kellner A, Normann C, Heinrichs M, Domes G

Journal of psychiatric research11 Jan 2023Cited by 7 (Europe PMC)

PMID36657314 (opens in a new tab)DOI10.1016/j.jpsychires.2023.01.016 (opens in a new tab)PepBankPUB-36657314
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with chronic depression, a single dose of intranasal oxytocin had no effect on facial emotion recognition compared with placebo.

    In plain wordsIn people with chronic depression, one dose of oxytocin nasal spray did not change emotion recognition compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeFacial emotion recognition
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    Dose not stated · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    In emotion recognition, CDD patients were not more impaired than healthy controls, and there was no OT effect.
    1 context sentence
    Summary · context
    The present study thus investigated potential alterations in gaze preferences during a standardized facial emotion recognition (FER) task using remote eye tracking in patients with CDD and the effect of a single dose of intranasal OT (compared to placebo).
  2. 02HumanNon-randomized trialMechanism

    In patients with chronic depression, the lower attentional preference for the eye region seen with placebo was not apparent after intranasal oxytocin.

    In plain wordsIn people with chronic depression, the lower attention to the eyes seen with placebo was not apparent after oxytocin nasal spray.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedAttention to the eye region during emotion recognition
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    Dose not stated · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    However, CDD patients (with placebo) demonstrated less attentional preference for the eye region during FER than healthy controls, which was not apparent in the CDD group after OT treatment.
    1 context sentence
    Summary · context
    The present study thus investigated potential alterations in gaze preferences during a standardized facial emotion recognition (FER) task using remote eye tracking in patients with CDD and the effect of a single dose of intranasal OT (compared to placebo).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.